CYP2C19 POCT
Point-of-care molecular testing (POCT) of CYP2C19 for optimisation of antiplatelet therapy (Artificial Buccal swabs)
Overview
The scheme is designed to assess the analytical process (genotyping) only.
At a glance
Product Code:
07-POCT-CYP2C19-27
Target/Genes:
CYP2C19 variants *2, *3, *4 and *17
Technology:
PCR based
Sample Type:
Artificial Buccal Swab
Submit Results In:
Not applicable
Accredited:
No
Key Dates
22/10/2027
Every 3 months
4 weeks after sample dispatch
Sample Details
EQA Results
The user will receive a survey report containing device specific performance data, benchmarked against the cohort of participating users.
Participation Information
Point-of-Care testing for CYP2C19 *2, *3, *4, and *17 variants.
Users will receive two EQA samples every three months (8 samples per year), allowing them to verify the ongoing accuracy of CYP2C19 testing on their POCT devices, to ensure patients receive the most reliable diagnoses possible.
Users are required to report CYP2C19 *2, *3, *4, and *17 detection status, with additional patient identifiers.
Additional samples are available to purchase for device verification. You can purchase a verification package of materials from our website by navigating to the ‘Our EQA Schemes’ section, selecting ‘Buy an EQA Scheme,’ and searching for ‘DVS.’
No restrictions on number of participants. Open to laboratories from ALL countries (note: some restrictions may apply due to sanctions, delivery network exceptions, restrictions on importation etc).
Send your enquiry by submitting the form
Closes in 347 days
From £1200.00
Buying is completed on the EMQN portal and needs a free EMQN account, which takes a few minutes to set up.
Questions about this scheme?
Contact our team
Register Interest
Express your interest in ''.